Atıf İçin Kopyala
TELLİ G., TEL B. C., Gumusel B.
Turkish Journal of Pharmaceutical Sciences, cilt.17, sa.3, ss.349-356, 2020 (ESCI)
-
Yayın Türü:
Makale / Derleme
-
Cilt numarası:
17
Sayı:
3
-
Basım Tarihi:
2020
-
Doi Numarası:
10.4274/tjps.galenos.2019.47123
-
Dergi Adı:
Turkish Journal of Pharmaceutical Sciences
-
Derginin Tarandığı İndeksler:
Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, International Pharmaceutical Abstracts, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.349-356
-
Anahtar Kelimeler:
CGRP family, cardiopulmonary diseases, adrenomedullin, adrenomedullin2, intermedin, pulmonary hypertension, VASCULAR SMOOTH-MUSCLE, PULMONARY ARTERIAL-HYPERTENSION, ACTIVITY-MODIFYING PROTEINS, INCREASED PLASMA-LEVELS, CENTRAL-NERVOUS-SYSTEM, NITRIC-OXIDE, REGIONAL HEMODYNAMICS, SIGNAL-TRANSDUCTION, ENDOTHELIAL-CELLS, DEPENDENT PATHWAY
-
Lokman Hekim Üniversitesi Adresli:
Evet
Özet
© Turk J Pharm Sci, Published by Galenos Publishing House.Cardiopulmonary diseases are very common among the population. They are high-cost diseases and there are still no definitive treatments. The roles of members of the calcitonin-gene related-peptide (CGRP) family in treating cardiopulmonary diseases have been studied for many years and promising results obtained. Especially in recent years, two important members of the family, adrenomedullin and adrenomedullin2/intermedin, have been considered new treatment targets in cardiopulmonary diseases. In this review, the roles of CGRP family members in cardiopulmonary diseases are investigated based on the studies performed to date.